A Phase 3, Open-Label, Multicenter, Single-Arm Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of Dulaglutide 3.0 mg and 4.5 mg in Pediatric Participants 10 to Less than 18 Years of Age with Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)
-
Enrollment
This study is currently enrolling. -
Associated Conditions
-
Research Area
Pediatric Research and Clinical Trials -
Location
-
Principal Investigator
-
Sponsor
Eli Lilly
This study will help us learn more about a study drug called dulaglutide. We are testing this study drug to find out if it helps kids and teens who have T2DM. We also want to find out if this study drug causes any unwanted reactions.
Enrollment Form
This study is currently enrolling.